| General Information | |
|---|---|
| ZINC ID | ZINC000072111408 |
| Molecular Weight (Da) | 505 |
| SMILES | Cc1c(C(=O)NC(C)(C)c2nnn(C)n2)nn(-c2ccc(Cl)cc2Cl)c1-c1ccc(Cl)cc1 |
| Molecular Formula | C22Cl3N7O1 |
| Action | Antagonist |
| Physicochemical Details | |
|---|---|
| Molar Refractivity | 132.619 |
| HBA | 5 |
| HBD | 1 |
| Rotatable Bonds | 5 |
| Heavy Atoms | 33 |
| LogP | 6.169 |
| Activity (Ki) in nM | 87.0964 |
| Polar Surface Area (PSA) | 90.52 |
| Pharmacokinetic Properties (AdmetSAR) | |
|---|---|
| Human intestinal absorption | + |
| Caco-2 | - |
| Blood brain barrier | + |
| P-glycoprotein inhibitior | + |
| P-glycoprotein substrate | - |
| Cyp3a4 substrate | + |
| Cyp2c9 substrate | - |
| Cyp2d6 substrate | - |
| Cyp3a4 inhibition | - |
| Cyp2c9 inhibition | + |
| Cyp2c19 inhibition | + |
| Cyp2d6 inhibition | - |
| Cyp1a2 inhibition | - |
| Acute oral toxicity | + |
| Carcinogenicity (binary) | - |
| Ames mutagenesis | - |
| Human ether-a-go-go-related gene inhibition | + |
| Biodegradation | - |
| Glucocorticoid receptor binding | + |
| Thyroid receptor binding | + |
| Androgen receptor binding | + |
| Plasma protein binding | 0.896 |
| Pharmacokinetic Properties (SwissADME) | |
|---|---|
| Number of aromatic heavy atoms | 22 |
| Fraction csp3 | 0.23 |
| Ilogp | 4.41 |
| Xlogp3 | 5.73 |
| Wlogp | 4.89 |
| Mlogp | 4.53 |
| Silicos-it log p | 4.24 |
| Consensus log p | 4.76 |
| Esol log s | -6.68 |
| Esol solubility (mg/ml) | 0.000106 |
| Esol solubility (mol/l) | 0.00000021 |
| Esol class | Poorly sol |
| Ali log s | -7.4 |
| Ali solubility (mg/ml) | 0.0000202 |
| Ali solubility (mol/l) | 0.00000004 |
| Ali class | Poorly sol |
| Silicos-it logsw | -8.49 |
| Silicos-it solubility (mg/ml) | 0.00000163 |
| Silicos-it solubility (mol/l) | 3.23E-09 |
| Silicos-it class | Poorly soluble |
| Pgp substrate | |
| Log kp (cm/s) | -5.31 |
| Lipinski number of violations | 2 |
| Ghose number of violations | 1 |
| Veber number of violations | 0 |
| Egan number of violations | 0 |
| Muegge number of violations | 1 |
| Bioavailability score | 0.17 |
| Pains number of alerts | 0 |
| Brenk number of alerts | 0 |
| Leadlikeness number of violations | 2 |
| Synthetic accessibility | 3.54 |
| Pharmacokinetic Properties (ADMETLab) | |
|---|---|
| Logs | -6.037 |
| Logd | 4.572 |
| Logp | 4.803 |
| F (20%) | 0.005 |
| F (30%) | 0.038 |
| Mdck | - |
| Ppb | 99.20% |
| Vdss | 1.643 |
| Fu | 1.73% |
| Cyp1a2-inh | 0.272 |
| Cyp1a2-sub | 0.807 |
| Cyp2c19-inh | 0.933 |
| Cyp2c19-sub | 0.73 |
| Cl | 7.061 |
| T12 | 0.042 |
| H-ht | 0.282 |
| Dili | 0.984 |
| Roa | 0.487 |
| Fdamdd | 0.691 |
| Skinsen | 0.085 |
| Ec | 0.003 |
| Ei | 0.009 |
| Respiratory | 0.361 |
| Bcf | 1.954 |
| Igc50 | 4.262 |
| Lc50 | 5.499 |
| Lc50dm | 5.008 |
| Nr-ar | 0 |
| Nr-ar-lbd | 0.01 |
| Nr-ahr | 0.601 |
| Nr-aromatase | 0.938 |
| Nr-er | 0.681 |
| Nr-er-lbd | 0.042 |
| Nr-ppar-gamma | 0.029 |
| Sr-are | 0.883 |
| Sr-atad5 | 0.006 |
| Sr-hse | 0.012 |
| Sr-mmp | 0.838 |
| Sr-p53 | 0.493 |
| Vol | 457.242 |
| Dense | 1.1 |
| Flex | 0.261 |
| Nstereo | 0 |
| Nongenotoxic carcinogenicity | 1 |
| Ld50 oral | 0 |
| Genotoxic carcinogenicity mutagenicity | 0 |
| Surechembl | 0 |
| Nonbiodegradable | 1 |
| Skin sensitization | 1 |
| Acute aquatic toxicity | - |
| Toxicophores | 1 |
| Qed | 0.413 |
| Synth | 2.841 |
| Fsp3 | 0.227 |
| Mce-18 | 27 |
| Natural product-likeness | -1.508 |
| Alarm nmr | 0 |
| Bms | 0 |
| Chelating | 0 |
| Pfizer | - |
| Gsk | Rejected |
| Goldentriangle | Rejected |